SAN DIEGO -- Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without ...

For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high risk for ...

Medical Watch Digest for Dec. 9 Acute lymphoblastic leukemia highest survival rate among pediatric cancers Survival rates for ...

Brexucabtagene autoleucel showed comparable efficacy outcomes in patients aged 60 to 69 with relapsed/refractory B-cell acute ...

For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an ...

Chemotherapy and Blinatumomab improve survival rates in common childhood leukemia (B-cell acute lymphoblastic leukemia or B-ALL).

A newly approved immunotherapy can help adults with a difficult-to-treat form of leukemia, clinical trial results show ...

B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among ...

Researchers from Children's Hospital of Philadelphia (CHOP) have discovered the underlying biology that identifies a subset ...

Ten years after its first FDA approval, Amgen’s Blincyto continues to make inroads in treating acute lymphoblastic leukemia. | Investigators halted study randomization early based on the strong ...

Opens in a new tab or window SAN DIEGO -- Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without disease recurrence when they received the ...

Just days before his fourth birthday, Santiago was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), the most common cancer in children. He began chemotherapy the next day, and the ...